B
Bivash Mandal
Researcher at University of Tennessee Health Science Center
Publications - 17
Citations - 761
Bivash Mandal is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Targeted drug delivery & Drug delivery. The author has an hindex of 10, co-authored 17 publications receiving 648 citations. Previous affiliations of Bivash Mandal include Indian Institute of Chemical Biology & Jadavpur University.
Papers
More filters
Journal ArticleDOI
Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform
Bivash Mandal,Himanshu Bhattacharjee,Nivesh K. Mittal,Hongkee Sah,Pavan Balabathula,Laura A. Thoma,George C. Wood +6 more
TL;DR: This comprehensive review covers the current applications of core-shell-type lipid-polymer hybrid nanoparticles, which combine the mechanical advantages of biodegradable polymeric nanoparticles and biomimetic advantages of liposomes to enable an efficient drug delivery system.
Journal ArticleDOI
Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer
TL;DR: Evaluated in vitro cellular efficacy results indicated enhanced uptake and efficacy of erlotinib loaded CSLPHNPs compared to erlotInib solution in A549 cells, a human lung adenocarcinoma cell line, and CSL PHNPs could be a potential delivery system for erlot inib in the therapy of NSCLC.
Journal ArticleDOI
Preparation and Physicochemical Characterization of Eudragit ® RL100 Nanosuspension with potential for Ocular Delivery of Sulfacetamide
TL;DR: In this paper, a formulation of sulfacetamide in Eudragit® RL100 nanosuspension could be used as potential delivery system for treating ocular bacterial infections.
Journal Article
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
TL;DR: The results indicate that the formulation of sulfacetamide in Eudragit® RL100 nanosuspension could be utilized as potential delivery system for treating ocular bacterial infections.
Journal ArticleDOI
Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: formulation, characterization, technetium-99m labeling and biodistribution studies.
Kamal Krishna Halder,Bivash Mandal,Mita Chatterjee Debnath,Hriday Bera,Lakshmi Kanto Ghosh,Bijon Kumar Gupta +5 more
TL;DR: The CHL-loaded PLGA NPs coated with PS-80 exhibited relatively high brain uptake with comparatively low accumulation in bone marrow to that of free drug and CHL/PVA NPs (PVA, used as emulsion stabilizer) at 24 h post injection time period indicates the usefulness of the above delivery system for prolonged use of the antibiotic.